Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACH-0145548 in Healthy Participants

Trial Profile

A Randomized, Double-Blind, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACH-0145548 in Healthy Participants

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2018

At a glance

  • Drugs ACH-5548 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions; First in man
  • Sponsors Achillion Pharmaceuticals
  • Most Recent Events

    • 07 Nov 2018 According to an Achillion Pharmaceuticals media release, the company has announced that it plans to provide interim data from this trial on December 17, 2018.
    • 08 Aug 2018 According to an Achillion Pharmaceuticals media release, the company expect to provide data and a strategic update in December 2018.
    • 10 Jul 2018 According to an Achillion Pharmaceuticals media release, the company has initiated dosing the healthy volunteer in this study. Interim results from this study is anticipated in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top